SC
RLAY icon

SMA Capital’s Relay Therapeutics RLAY Stock Holding History

SMA Capital’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.3K Buy
+552
New +$8.01K ﹤0.01% 115

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

SMA Capital's RLAY Position: Q2 2026 in Review

SMA Capital opened a new position in Relay Therapeutics (RLAY) in Q2 2026: 552 shares worth $10.3K. The stake represents ﹤0.01% of the portfolio and ranks #115 among its holdings.

258 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • SMA Capital held 552 shares of Relay Therapeutics worth $10.3K as of Q2 2026.
  • Relay Therapeutics was a new SMA Capital position in Q2 2026.
  • Relay Therapeutics made up ﹤0.01% of SMA Capital's portfolio in Q2 2026, its #115 holding.
  • 258 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on SMA Capital's 13F filing for Q2 2026, filed 14 Aug 2026.